#JohnsonandJohnson's #Tecvayli has been approved as part of a #combinationregimen with its #Genmab-partnered #DarzalexFaspro as a second-line therapy for relapsed or refractory #multiplemyeloma, just 55 days after it was filed with the FDA.

pharmaphorum.com/news/jjs-tec...